Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

CervoMed (CRVO) Enterprise Value (2022 - 2025)

CervoMed's Enterprise Value history spans 9 years, with the latest figure at -$27.3 million for Q3 2025.

  • For Q3 2025, Enterprise Value rose 29.86% year-over-year to -$27.3 million; the TTM value through Sep 2025 reached -$27.3 million, up 29.86%, while the annual FY2024 figure was -$38.9 million, 399.46% down from the prior year.
  • Enterprise Value for Q3 2025 was -$27.3 million at CervoMed, up from -$33.5 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$6.4 million in Q1 2024 and bottomed at -$45.1 million in Q2 2024.
  • The 4-year median for Enterprise Value is -$27.3 million (2025), against an average of -$25.3 million.
  • The largest annual shift saw Enterprise Value soared 63.89% in 2024 before it crashed 453.36% in 2025.
  • A 4-year view of Enterprise Value shows it stood at -$16.5 million in 2022, then surged by 52.78% to -$7.8 million in 2023, then crashed by 399.46% to -$38.9 million in 2024, then rose by 29.87% to -$27.3 million in 2025.
  • Per Business Quant, the three most recent readings for CRVO's Enterprise Value are -$27.3 million (Q3 2025), -$33.5 million (Q2 2025), and -$35.2 million (Q1 2025).